Official websites use .gov
A
.gov website belongs to an official government
organization in the United States.
Secure .gov websites use HTTPS
A
lock (
) or https:// means you’ve safely connected to
the .gov website. Share sensitive information only on official,
secure websites.
In this webinar, Dr. Charles Peloquin presents information on the epidemiology of TB in the US. Dr. Peloquin also discusses emerging treatments for latent TB infection and for active TB disease.
The webinar presents information about interactions between TB medications and other drugs. This webinar is intended for physicians, nurses, and health professionals who treat and manage the care of patients with TB and LTBI.
In this webinar, Dr. Michael Lauzardo presents a brief information on the history of human trafficking. Dr. Lauzardo also shares ways to identify victims. Additionally, Dr. Lauzardo describes ways to address TB prevention and care to improve the health outcomes of victims.
In this webinar, Dr. David Ashkin presents information on the clinical significance of tuberculosis (TB) and hepatitis C virus (HCV). Dr. Ashkin also shares information on adverse effects that can occur during treatment, as well as strategies for treatment completion and optimal management of patients with HCV and TB.
This playlist contains videos for the North American Region Post Graduate course (2021). There are five videos in the playlist:
1. "Welcome and Overview" is presented by Max Salfinger, MD, FAAM, FIDSA, ATSF and Connie Haley, MD. "The Role of the Laboratory in the Diagnosis & Management of TB" is presented by Angela Starks, PhD and Beverly Metchock, DrPH.
2. "Diagnostic Challenges" is presented by Amee Patrawalla, MD and Connie Haley, MD.
HIVMA created this document as a reference for HIV clinicians and educators across the trainee and provider continuum to help improve the delivery of HIV care and prevention. The resources include guidelines, clinical decision-making tools, continuing education opportunities, provider directories and other resources. Click on the links below for quick access to a section of interest.
This material was developed for clinicians to use with patients that are prescribed the three months of daily isoniazid plus rifampin (3HR) regimen for the treatment of latent TB infection. There is space to write treatment information, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 3HR regimen.
This material was developed for clinicians to use with patients that are prescribed the four months daily rifampin (4R) regimen for the treatment of latent TB infection. There is space to write treatment information, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 4R regimen.
This material was developed for clinicians to use with patients that are prescribed the 12-dose regimen for the treatment of latent TB infection. There is space to write treatment schedules, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 12-dose regimen.
The patient education brochure was developed for clinicians to use with patients while discussing the 12-dose regimen for the treatment of latent TB infection. The brochure contains information on latent TB infection, the 12-dose regimen, and adverse events.
